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Objectives The aim of this study was to determine the long-term effects of cardiac resynchronization therapy (CRT) in the
European cohort of patients enrolled in the REVERSE (Resynchronization Reverses Remodeling in Systolic Left
Ventricular Dysfunction) trial.
Background Previous data suggest that CRT slows disease progression and improves the outcomes of asymptomatic or
mildly symptomatic patients with left ventricular (LV) dysfunction and a wide QRS complex.
Methods We randomly assigned 262 recipients of CRT pacemakers or defibrillators, with QRS 120 ms and LV ejection
fraction 40% to active (CRT ON; n  180) versus control (CRT OFF; n  82) treatment, for 24 months. Mean
baseline LV ejection fraction was 28.0%. All patients were in sinus rhythm and receiving optimal medical ther-
apy. The primary study end point was the proportion worsened by the heart failure (HF) clinical composite re-
sponse. The main secondary study end point was left ventricular end-systolic volume index (LVESVi).
Results In the CRT ON group, 19% of patients were worsened versus 34% in the CRT OFF group (p  0.01). The LVESVi de-
creased by a mean of 27.5  31.8 ml/m2 in the CRT ON group versus 2.7  25.8 ml/m2 in the CRT OFF group (p 
0.0001). Time to first HF hospital stay or death (hazard ratio: 0.38; p  0.003) was significantly delayed by CRT.
Conclusions After 24 months of CRT, and compared with those of control subjects, clinical outcomes and LV function were
improved and LV dimensions were decreased in this patient population in New York Heart Association functional
classes I or II. These observations suggest that CRT prevents the progression of disease in patients with asymp-
tomatic or mildly symptomatic LV dysfunction. (REsynchronization reVErses Remodeling in Systolic Left vEntricu-
lar Dysfunction [REVERSE]; NCT00271154) (J Am Coll Cardiol 2009;54:1837–46) © 2009 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.08.011R
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(CRT), alone or in combination
with an implantable cardioverter-
defibrillator (ICD), is recom-
mended as a class I indication
level of evidence A for patients
presenting in New York Heart
Association (NYHA) heart fail-
ure (HF) functional class III or
IV, a wide QRS, and left ventric-
ular (LV) dysfunction (1,2). In
this population, CRT alleviates
symptoms and lowers major HF
morbidity, all-cause mortality
(3–7), and the risk of sudden
death (8). Cardiac resynchroni-
zation therapy also induces pro-
ressive changes in LV structure and function, consistent
ith reverse remodeling, most prominent in patients with
onischemic heart disease (9,10).
See page 1847
On the basis of these observations and the results of
revious small-size studies of patients in NYHA functional
lasses I and II (11,12), we hypothesized that CRT is also
eneficial in mildly symptomatic or asymptomatic patients
ith LV dysfunction and markers of cardiac dyssynchrony,
rimarily by preventing the progression of disease over the
ong term (10). The randomized, double-blind REVERSE
Resynchronization Reverses Remodeling in Systolic Left
entricular Dysfunction) trial was designed to test this
ypothesis (13). The primary end point of the study was the
roportion of patients worsened according to the 12-month
linical composite response, which was not significantly
ifferent between the actively treated (CRT ON) group and
he control (CRT OFF) group (p  0.10). A key secondary
bservation made in the first 12 months was a significantly
reater degree of reverse ventricular remodeling in the
ctively treated than in the control group (14). All patients
nrolled in the trial participated in the first 12 months of the
tudy, at which time the North American patients learned
heir randomization assignment. However, the European
ohort was prospectively randomized for 24 months. We
eport these long-term follow-up results in this article.
ethods
he present report refers to the European cohort of patients
nrolled in the REVERSE trial. Patients eligible for the
rial presented in American College of Cardiology/
merican Heart Association stage C (2), NYHA functional
lass I (previously symptomatic, currently asymptomatic) or
lass II (mildly symptomatic), for at least 3 months before
nrollment. They were in sinus rhythm, with a 120-ms or
Abbreviations
and Acronyms
CRT  cardiac
resynchronization therapy
HF  heart failure
ICD  implantable
cardioverter-defibrillator
LVEF  left ventricular
ejection fraction
LVESVi  left ventricular
end-systolic volume index
NYHA  New York Heart
Association
SAE  serious adverse
eventonger QRS duration, a left ventricular ejection fraction mLVEF) 40%, and a 55-mm or wider LV end-diastolic
iameter, measured by echocardiography. All patients were
eing treated with optimal medical therapy for HF (1)
ncluding stable doses of an angiotensin-converting enzyme
nhibitor or angiotensin II receptor blocker and a beta-
drenergic blocker for at least 3 months. Patients that were,
ithin 3 months before enrollment, in NYHA functional
lass III or IV or were hospitalized for HF were excluded
rom the study. Patients in need of permanent cardiac
acing or presenting with permanent or persistent atrial
achyarrhythmias were also excluded. Other exclusion cri-
eria were published previously (13). The ethics committee
f each participating center approved the study protocol,
nd all patients granted their written informed consent.
tudy design and procedures. Patients meeting the study
nclusion criteria underwent a baseline evaluation, including
YHA functional classification, quality-of–life assessment
y the Minnesota Living with Heart Failure questionnaire
nd the Kansas City Cardiomyopathy Questionnaire (15), a
-min hall-walk test, a 12-lead electrocardiogram for mea-
urement of QRS duration, and a 2-dimensional Doppler-
ow echocardiogram to assess the ventricular structure and
unction and the degree of mitral regurgitation. After this
valuation, the patients underwent implantation of CRT
acemaker or CRT defibrillator systems, depending on ICD
ndication. Patients who had undergone successful implan-
ation were randomly assigned in a 2-to-1 scheme to a CRT
N or CRT OFF group for 24 months. Randomization
ccurred in permuted blocks within each center. The device
f patients assigned to CRT ON was programmed to pace
oth ventricles and inhibit atrial pacing, unless the intrinsic
ate was 35 beats/min or less. The pulse generator of
atients assigned to CRT OFF was programmed to inhibit
trial or ventricular pacing, unless the intrinsic rate was 35
eats/min or less. The atrioventricular delay was optimized
y echocardiography in all patients, regardless of the ran-
omization assignment, before the final programming (13).
or patients assigned to CRT ON, the atrioventricular
elay remained unchanged from the time of their discharge
rom the hospital until the end of the study, unless the LV
ead needed to be revised. The patients were followed at 1,
, 6, 12, 18, and 24 months.
linding procedures. The physicians caring for the pa-
ients and responsible for the management of HF when
atients were hospitalized were unaware of the pacing
ode. Quality-of-life questionnaires, patient global assess-
ents, NYHA functional classification, and 6-min walk
ests were performed by observers unaware of the random
reatment assignment. Device interrogations and program-
ing, 12-lead electrocardiograms, echocardiograms, and
acemaker follow-ups were performed by unblinded
bservers.
The investigators were instructed to report all adverse
vents, which were adjudicated by an independent Adverse
vent Advisory/Endpoint Committee unaware of the treat-
ent assignment. An unblinded, independent Data Moni-
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November 10, 2009:1837–46 CRT in Mild Heart Failureoring Committee reviewed the cumulative adverse events,
ospital stays, and deaths. Crossover from the randomly
ssigned to the alternate treatment was disallowed before
he 24-month assessment, except if a patient in either group
eveloped progression of HF to NYHA functional class III
r IV. Crossovers required prior communications between
he site investigator and a member of the Steering Com-
ittee and were only allowed as a last resort.
tudy end points. The primary end point of the study was
he HF clinical composite response, used to classify patients
s worsened, unchanged, or improved (12,16). Patients were
lassified as worsened if they: 1) died or were hospitalized
or worsening HF; 2) crossed over to the alternate treatment
r permanently discontinued double-blind treatment due to
orsening HF; or 3) had an increase in NYHA functional
lass or a moderate or marked worsening in their overall
linical status. Patients were classified as improved if they
ad not worsened and had a decrease in NYHA functional
lass or had a moderate or marked improvement in their
verall clinical status or both. Patients who were neither
orsened nor improved were classified as unchanged.
The prospectively powered secondary end point was left
entricular end-systolic volume index (LVESVi), measured
s the absolute change between baseline and end follow-up
nd compared between the 2 study groups. All European
chocardiographic measurements were made by a single
ore laboratory.
dverse events. At each follow-up evaluation and up to
he 24-month follow-up, all adverse events, whether related
r unrelated to CRT, were recorded. Any event that led to
eath or to serious deterioration in the health status—
eaning a life-threatening illness or injury resulting in a
ermanent impairment, required hospital stays or prolon-
ation of hospital stay, or medical or surgical intervention—
as classified as a serious adverse event (SAE).
tatistical analysis. The data were analyzed according to
he intention-to-treat principle for all randomized patients.
or the pre-specified analysis of the primary end point,
atients who were improved or unchanged were grouped
nd considered to have suffered no progression of HF,
hereas the proportion of patients who worsened in each
tudy group was compared to ascertain the efficacy of CRT.
or all time-to-event analyses, the Kaplan-Meier method
as used, and groups were compared with log-rank statis-
ics. Time 0 was the date of randomization, and patients
ho did not experience an event were censored at the
4-month follow-up or on the date of their exit from the
tudy. The proportions of patients who suffered at least 1
AE in each study group were compared with Fisher exact
est. Rates of SAE are reported as the number of SAE
ivided by the study sample size. Other between-groups
omparisons were made with Fisher exact test (proportions)
r Student 2-sample t test (means). The HF clinical
omposite response (percent of patients worsened) is re-
orted as the observed odds ratio of CRT ON to CRT
FF, and 95% Wald confidence limits were used. Location Hata are reported as mean  SD. All p values are nominal,
nd all statistical tests were 2-sided. The threshold of
ignificance was set at 0.05.
esults
tudy population. A total of 287 patients were enrolled in
he study at 35 European medical centers, between Decem-
er 2004 and September 2006. The baseline evaluation was
ompleted in 277 (Fig. 1). The CRT implants were at-
empted in 274 and successfully performed in 266 patients,
epresenting a 97% overall implantation success rate. The
RT defibrillators were implanted in 68% and CRT pace-
akers were implanted in 32% of patients. The mean
VEF was 28.0  6.8% and mean left ventricular end-
iastolic dimension was 70  9 mm. The mean QRS
uration was 156 23 ms. At the time of study enrollment,
n angiotensin-converting enzyme inhibitor or angiotensin
eceptor blocker was being administered to 99.6%, and a
eta-adrenergic blocker was being administered to 93.5% of
atients. Target doses of beta-adrenergic blockers were
dministered to 36% of patients, whereas 62% were receiv-
ng at least 50% of the target dose recommended by current
F guidelines (1). Ultimately, 262 patients were randomly
ssigned to CRT ON (n 180) versus CRT OFF (n 82).
he baseline characteristics of the 2 study groups were
imilar (Table 1).
uropean sample versus remainder of the REVERSE
rial population. In the REVERSE trial, several important
aseline characteristics of the European subgroup differed
rom the remainder of the study population (i.e., non-
uropean participants) (14) (Table 2). Overall, compared
ith the non-European sample, the European sample was,
n average, significantly younger with fewer comorbidities.
hus European patients had a lower mean prevalence of
schemic heart disease (44% vs. 63%; p  0.0001), less
eripheral artery disease, and less history of prior myocardial
nfarction (34% vs. 55%; p  0.0001) and of hypertension
34% vs. 66%; p  0.0001). Moreover, Europeans had a
maller body mass index and a longer mean QRS duration
156 23 ms vs. 151 21 ms; p 0.008), covered a longer
ean 6-min walk distance (439  103 m vs. 363  134 m;
 0.0001), and had a smaller proportion of CRT
efibrillators implanted (68% vs. 95%; p  0.0001) com-
ared with the non-European patients.
ffect of CRT on primary and secondary end points.
he difference between the 2 study groups became statisti-
ally significant at the 6-month evaluation and continued to
iffer significantly and with a similar amplitude of difference
ver the entire follow-up period in favor of the CRT ON
ssignment (Fig. 2). At 24 months of follow-up, a worsen-
ng of the HF clinical composite response was observed in
4 of the 180 patients (19%) assigned to CRT ON
ompared with 28 of the 82 patients (34%) assigned to CRT
FF (p  0.01). Worsening was attributable to death or
F hospital stays in 68% of worsened patients in the CRT
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CRT in Mild Heart Failure November 10, 2009:1837–46FF group. Analyzing the HF clinical composite response
onventionally by using the entire distribution of worsened,
nchanged, and improved (16) yielded a p value of 0.0006 at
4 months in favor of CRT ON.
Paired measurements of LVESVi were available for 187
f the 262 patients (71%). The reasons for missing data are
eported in Table 3. Intraobserver and interobserver vari-
bility for LVESVi in the echocardiographic core laboratory
ave been previously published (17). The LVESVi de-
reased by a mean of 27.5  31.8 ml/m2 in the CRT ON
n  136) compared with 2.7  25.8 ml/m2 in the CRT
FF (n 51) group (p 0.0001) (Fig. 3). In the CRT ON
roup, the decrease in LVESVi was more than twice as
reat (36.9  32.4 ml/m2) among patients with nonisch-
mic heart disease as among patients with ischemic heart
isease (16.3  27.3 ml/m2). The measurements of left
entricular end-diastolic volume index and LVEF revealed
imilarly greater changes, consistent with reverse remodel-
ng, in the CRT ON than in the CRT OFF group (Fig. 3).
he main ventricular remodeling effect conferred by CRT
ccurred during the first 6 months, with further improve-
Figure 1 Study Flowchart
CRT off  control group; CRT on  actively treated group.ents developing over the following 12 months. subgroup analyses. Subgroup analyses yielded concordant
esults (Fig. 4). The improvements in clinical status and LV
unction conferred by CRT were significant and similar in
atients with ischemic and nonischemic heart disease. A
rend was observed toward less clinical efficacy conferred by
RT among patients in NYHA functional class I than in
lass II, though the statistical comparison was unreliable
ecause of an insufficient number of observations. Patients
ith a QRS duration 152 ms tended to derive more
enefit from CRT than patients with a QRS shorter than
52 ms.
ther secondary end points. The distance covered during
he baseline 6-min hall walk test was consistent with the
linical status of the study population. The mean changes in
he distance walked at 24 months (29.2  87.3 m with
RT ON vs. 21.9  90.7 m with CRT OFF; p  0.57)
nd quality of life ascertained by the Minnesota question-
aire score (8.2  15.5 with CRT ON vs. 7.0  14.6
ith CRT OFF; p  0.62) did not differ between groups.
ospital stays and death. During the 24-month follow-
p, 106 of the 262 patients underwent a total of 199 hospital
tays. In the CRT ON group, 40.5% of patients were
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November 10, 2009:1837–46 CRT in Mild Heart Failureospitalized for any cause versus 41.2% of patients in the
RT OFF group (hazard ratio [HR]: 0.98, p  0.94). The
ime to first HF hospital stay was significantly longer in the
RT ON (7.8% hospitalized) than in the CRT OFF
18.4%) group (HR: 0.39, p  0.01).The absolute rates of
F hospital stay were 14 of 82 (17.1%) CRT OFF patients
nd 13 of 180 (7.2%) CRT ON patients. Time to first HF
ospital stay or death, time to first HF hospital stay, and
ime to death from any cause are displayed in Figure 5.
During the 24-month follow-up, 13 patients died.
eaths were classified as sudden cardiac in 3 patients and
F-related in 3 patients and due to noncardiovascular causes
n 4 patients. No cause of death was identified in 3 patients.
he 24-month death rate was 5.7% in the CRT ON versus
.6% in the CRT OFF group (HR: 0.40, p  0.09).
dverse events. The perioperative (0 to 30 days) SAE rate
as 21%, consisting mainly of dislodgments of 13 left
entricular, 6 right atrial, and 5 right ventricular leads. After
mplantation and during the 24-month follow-up, 26 of the
aseline Characteristics of Study GroupsTable 1 Baseline Characteristics of Study Groups
Age, yrs
Men
New York Heart Association functional class II
Ischemic heart disease
Previous myocardial infarction
Diabetes
History of hypertension
Peripheral vascular disease
Angiotensin-converting enzyme inhibitor
Angiotensin-converting enzyme inhibitor or ARB
Beta-adrenergic blocker
50% of target beta-adrenergic blocker dose
100% of target beta-adrenergic blocker dose
Diuretic
Intrinsic QRS duration, ms
Left ventricular
Ejection fraction, %
End-systolic volume, cm3
End-diastolic volume, cm3
Interventricular mechanical delay, ms
Glomerular filtration rate, ml/min
Heart rate, beats/min
Supine blood pressure, mm Hg
Systolic
Diastolic
Body weight, kg
Body mass index, kg/m2
Minnesota Living With Heart Failure score
Kansas City Cardiomyopathy Questionnaire summary score
6-min hall walk, m
CRT-D implanted
alues are mean  SD or percent of patients in corresponding group.
ARB  angiotensin receptor blocker; CRT-D  cardiac resynchronization therapy defibrillator; C62 device recipients experienced a total of 30 device-related fAE. The percentage of patients with SAE in the CRT
N versus CRT OFF study groups were similar (p 0.66).
he rate of SAE between 1 and 12 months was 6%, the
ost common SAE being lead dislodgement, particularly of
he LV lead (n  9). The rate of SAE between 12 and 24
onths was 3%, consisting mainly of right ventricular lead
ysfunction. At the time of study closure, 29 of the 30
ost-implant, device-related SAE were resolved.
ollow-up compliance and crossovers. In addition to the
3 deaths, there were 4 exits from the study before 24
onths. The 24-month follow-up was completed by the
ther 245 patients. During the 24 months, 15 of the 262
atients (5.7%) permanently crossed over from their ran-
omized assignment to the alternate treatment, including 2
atients from CRT ON to CRT OFF due to worsening HF
nd upon the patient’s request, respectively, and 13 patients
rom CRT OFF to CRT ON, because of worsening HF in
0 and other reasons in 3 patients. Crossover due to
orsening HF occurred at various times during follow-up
CRT OFF
(n  82)
CRT ON
(n  180)
60.4 11.2 61.7 10.0
85% 79%
84% 83%
41% 44%
35% 33%
17% 14%
38% 32%
2% 7%
84% 87%
100% 99%
90% 95%
62% 62%
35% 37%
87% 84%
157 25 155 22
27.8 5.8 28.1 7.2
186 58 186 75
257 74 256 91
37.2 35.3 37.9 37.9
85.9 32.0 83.3 31.6
66.5 11.1 65.9 10.0
125 18 126 18
73 11 73 11
85.4 14.0 80.9 14.9
28.3 4.3 27.5 4.1
27.2 20.0 24.9 17.3
68.3 21.0 72.9 18.1
430 103 442 104
72% 66%
 control group; CRT ON  actively treated group.rom 44 to 603 days after randomization.
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he 24-month results of the European cohort of the large
ulticenter REVERSE trial show for the first time that
RT improves the HF clinical composite response, a
easure of clinical outcome (16) as well as LV structure and
unction, in patients with asymptomatic or mildly symp-
omatic LV dysfunction. The CRT ON was associated with
rogressive reverse LV remodeling over time, which was
ignificant at 6 months of follow-up with a further improve-
ent over time and was accompanied by a significant
ecrease in morbidity and mortality. Not surprisingly, no
ignificant improvement in quality of life or increase in
xercise capacity by CRT was observed, an expected out-
ome in a cohort of patients with little functional impair-
ent at baseline.
The present results with a twice-as-long follow-up were
uperior to those observed in the first phase of the study, in
hich no significant difference was observed in the primary
nd point between the 2 study groups (14). This significant
omparative Baseline Characteristics in the European and in the NTable 2 Comparative Baseline Characteristics in the European
Age, yrs
Men
New York Heart Association functional class II
Ischemic heart disease
Previous myocardial infarction
Diabetes
History of hypertension
Peripheral vascular disease
Angiotensin-converting enzyme inhibitor
Angiotensin-converting enzyme inhibitor or ARB
Beta-adrenergic blocker
50% of target beta-adrenergic blocker dose
100% of target beta-adrenergic blocker dose
Diuretic
Intrinsic QRS duration, ms
Left ventricular
Ejection fraction, %
End-systolic volume, cm3
End-diastolic volume, cm3
Interventricular mechanical delay, ms
Glomerular filtration rate, ml/min
Heart rate, beats/min
Supine blood pressure, mm Hg
Systolic
Diastolic
Body weight, kg
Body mass index, kg/m2
Minnesota Living With Heart Failure score
Kansas City Cardiomyopathy Questionnaire summary score
6-min hall walk, m
CRT-D implanted
he p values compare European and non-European patients.
REVERSE  REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction triand sustained benefit conferred by CRT has several putative cxplanations. First, disease progression in patients present-
ng with NYHA functional class I or II is usually slow. Its
revention or reversal by any treatment modality might
equire several years to become apparent (18). In the present
tudy, the longer follow-up might have contributed to the
ighly significant results, manifest as progressive, time-
ependent, therapeutic effects conferred by CRT. It does
ot, however, explain how the primary objective was
eached as early as 6 months in the European cohort, in
ontrast to the main, much larger, 12-month study (14).
he effect of a different patient population might be an
mportant factor. The European cohort of the REVERSE
rial was representative of a typical European HF population
ith, in particular, a relatively low proportion of ischemic
eart disease, as observed in previous European trials of
RT with favorable outcomes (7). Although the influence
f underlying heart disease on the long-term outcomes of
RT systems recipients remains to be confirmed, its major
ffect on the rate and time course of reverse remodeling
ropean Cohorts of the REVERSE Trialin the Non-European Cohorts of the REVERSE Trial
opean
262)
Non-European
(n  348) p Value
 10.4 63.4 11.3 0.02
76% 0.16
82% 0.75
63% 0.0001
55% 0.0001
28% 0.0001
66% 0.0001
11% 0.02
73% 0.0001
95% 0.0003
96% 0.13
59% 0.62
35% 0.93
76% 0.006
 23 151 21 0.008
 6.8 26.2 6.4 0.001
 70 209 85 0.0006
 86 279 97 0.005
 37.0 30.4 40.3 0.04
 31.7 87.2 34.0 0.25
 10.3 68.2 10.5 0.01
 18 124 19 0.38
 11 71 11 0.10
 14.8 88.5 19.9 0.0001
 4.2 29.0 5.8 0.001
 18.2 28.9 22.1 0.05
 19.1 73.4 20.5 0.28
 103 363 134 0.0001
95% 0.0001
abbreviations as in Table 1.on-Euand
Eur
(n 
61.3
81%
83%
44%
34%
15%
34%
5%
86%
99%
94%
62%
35%
85%
156
28.0
186
256
37.7
84.1
66.1
125
73
82.3
27.7
25.6
71.4
439
68%onferred by CRT has been clearly established (9,10). As a
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November 10, 2009:1837–46 CRT in Mild Heart Failureatter of fact, in the present study the extent of reverse
emodeling among patients with nonischemic heart disease
fter CRT was more than 2 times greater than among
atients with ischemic heart disease.
The extent of reverse remodeling observed in the present
tudy was similar to that observed in previous studies of
RT in patients in NYHA HF functional classes III and IV
9,10). Importantly, a larger proportion of patients in the
Figure 2 The Primary End Point, the HF Clinical
Composite Response at 6, 12, 18, and 24 Months
The p values compare percent worsened in CRT OFF versus CRT ON at each
time point; n  262 European patients at each time point. Error bars are exact
95% confidence intervals. CRT OFF  control group; CRT ON  actively treated
group; HF  heart failure; NYHA  New York Heart Association.
easons for Missed LVESVi Paired DifferenceTable 3 Reasons for Missed LVESVi Paired Difference
Reason for Missed LVESVi Paired Data
Have paired data
No baseline, full echocardiogram not done
No baseline, LVESV on echocardiogram not readable
Died before 24 months
Exited before 24 months
No 24-month, full echocardiogram not done
No 24-month, LVESV on echocardiogram not readable
Total missingVESVi  left ventricular end-systolic volume index; other abbreviations as in Table 1.Figure 3 Effect of CRT on Left Ventricular
Dimensions and Function: Changes in Mean
(A) Left ventricular end systolic volume index (LVESVi), (B) left ventricular end
diastolic volume index (LVEDVi), and (C) left ventricular ejection fraction (LVEF)
between baseline and 24 months, in each study group. Error bars indicate 95%
confidence intervals. At each time point, all patients with data are included in the
mean calculation. CRT OFF  control group; CRT ON  actively treated group.CRT OFF
(n  82)
CRT ON
(n  180)
Total
(n  262)
51 (62%) 136 (76%) 187 (71%)
1 (1%) 0 (0%) 1 (1%)
5 (6%) 14 (8%) 19 (7%)
6 (7%) 6 (3%) 12 (5%)
2 (2%) 2 (1%) 4 (2%)
2 (2%) 1 (1%) 3 (1%)
15 (18%) 21 (12%) 36 (14%)
31 (38%) 44 (24%) 75 (29%)
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CRT in Mild Heart Failure November 10, 2009:1837–46EVERSE trial were treated with beta-adrenergic blockers
or at least 3 months before randomization than in these
revious trials, and a larger proportion of patients received
arget doses, with no changes in doses allowed during the
andomization phase, unless medically necessary. This sug-
ests that CRT has prominent effects on ventricular remod-
ling, above and beyond the effects of drugs prescribed for
he management of HF. This observation, along with the
igher survival associated with reverse LV remodeling (but
ot symptomatic improvement) reported by another study
ver 2 years (19), is consistent with the improvement in
linical outcomes observed in this study.
The mortality and hospital stay rates in the asymptomatic
r mildly symptomatic patient population of the RE-
ERSE trial were low, as expected. On average, the
atients were also younger, had a shorter mean QRS
uration, and were more rigorously managed at baseline
ccording to current HF guidelines (1) than in previous
rials. A clearly decreased morbidity and a trend toward a
ecreased mortality, attributable to CRT, were nevertheless
bserved in this study. Although the REVERSE trial was
ot designed to examine morbidity or mortality, our obser-
ations suggest that, in the long term, they might both be
Figure 4 Effect of CRT on the HF Clinical Composite Response
Analysis of the percentage of patients worsened, according to the HF clinical comp
ratios favor CRT ON. An odds ratio of 0.5 means that the likelihood of being worse
pressure, ejection fraction, end-systolic volume index, QRS width, interventricular m
median value in the entire study sample, including the U.S. patients. ICD  implaowered by CRT in patients presenting in NYHA func- eional class I or II. The long-term effects of CRT on
ortality and HF-related clinical events are currently being
tudied by the RAFT (Resynchronization/Defibrillation in
mbulatory Heart Failure) trial (20) and MADIT CRT
Multicenter Automatic Defibrillator Implantation Trial–
ardiac Resynchronization Therapy) trial (21).
The benefits conferred by CRT in a patient population
imilar to that of the REVERSE trial must be balanced
gainst its risks. Because most patients in the REVERSE
rial were candidates for the primary preventive implanta-
ion of an ICD (22), the added risk associated with the
ddition of a CRT system was related to the LV lead, which
as 11% at 24 months with most complications occurring
uring the 12 first months. Furthermore, the implant
uccess rate was very high, reflecting the progress made in
mplantation techniques and lead design since earlier studies
f CRT devices (3–5).
tudy limitations. Complete blinding is not feasible in
evice trials. In the present double-blind study, all precau-
ions were taken to limit potential bias due to blinding
rocedure. Most importantly, different staff members eval-
ated the device and patients outcome, including the elec-
rocardiograms and echocardiograms. Still, we cannot
ng Pre-Specified Study Subgroups
end point, with odds ratios and 95% confidence intervals (CIs). Lower odds
ith CRT ON is 50% of that with CRT OFF. The subgroups of age, systolic blood
nical delay (IVMD), and glomerular filtration rate are divided according to the
cardioverter-defibrillator; other abbreviations as in Figure 2.Amo
osite
ned w
echa
ntablexclude that some situations—like examining the electro-
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November 10, 2009:1837–46 CRT in Mild Heart Failureardiogram while evaluating the patient—would have
isclosed whether patients were programmed to CRT
N or CRT OFF and might have created the potential
or bias. The present analysis was conducted in the
uropean cohort of the study. Because there were some
mportant differences in baseline demographic data be-
ween European and non-European patients, we cannot
xclude that our results are in part explained by a
opulation effect. Thus, our conclusions are mainly
ppropriate for a European NYHA functional class I/II
F population. The REVERSE trial was planned to
nroll mildly symptomatic or asymptomatic HF patients
ith LV dysfunction. However, relatively few NYHA
unctional class I patients (17% of the entire study
opulation) were recruited. Accordingly, this article more
ccurately reports on the results of CRT in patients with
YHA functional class II HF. The relatively high
roportion of missing echocardiographic data is a com-
on observation in studies with centralized analysis
9 –11). In the present study, there are 2 main reasons for
he imbalance in paired data: deaths (7% CRT OFF vs.
% CRT ON) and nonreadable 24-month echocardio-
raph (18% CRT OFF and 12% CRT ON). Missing
chocardiographic data were more common in the CRT
FF group than in the CRT ON group, but a sensitivity
nalysis revealed that the results would be the same even
f we assumed outcomes in favor of CRT OFF over CRT
N for the missing patients.
onclusions
ver a 24-month follow-up, CRT improved the clinical
tatus, reduced the risk of first HF hospital stay or death,
nd reversed LV remodeling, in a large European popula-
ion of patients in NYHA functional classes I or II.
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